The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes

Wei Cho Li, V. Jayagopal, E. S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: There is an assumption that the mean and biological variation of insulin resistance (IR) is less in polycystic ovary syndrome (PCOS), and intuitively higher in type 2 diabetes (T2DM). To test this hypothesis we compared the mean and biological variation in IR in PCOS to that of T2DM and to age- and weight-matched controls. Methods: Twelve PCOS, 11 matched healthy women; 12 postmenopausal diet-controlled T2DM and 11 matched healthy postmenopausal women were recruited. Blood samples were collected at 4-d intervals on 10 consecutive occasions. The biological variability of IR was derived on duplicate samples. Results: Mean and biological variability of HOMA-IR for PCOS did not differ from T2DM. Both measures were higher than the matched controls. There was no difference in insulin or IR measures between the body mass index matched pre- and postmenopausal women. Percentage b cell function were 208.8%, 62.3%, 106.5% and 111.9%, respectively, in PCOS, postmenopausal women with T2DM, healthy premenopausal and healthy postmenopausal women. Conclusions: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. The clinical trial registration number for this study is ISRCTN65353256.

Original languageEnglish
Pages (from-to)218-221
Number of pages4
JournalAnnals of Clinical Biochemistry
Volume46
Issue number3
DOIs
Publication statusPublished - May 2009
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Medical problems
Type 2 Diabetes Mellitus
Insulin Resistance
Insulin
Insulin-Secreting Cells
Body Mass Index
Nutrition
Clinical Trials
Diet
Weights and Measures
Blood

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes. / Li, Wei Cho; Jayagopal, V.; Kilpatrick, E. S.; Atkin, Stephen.

In: Annals of Clinical Biochemistry, Vol. 46, No. 3, 05.2009, p. 218-221.

Research output: Contribution to journalArticle

@article{7cf197b5a5d446378aad2bc6de793bc0,
title = "The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes",
abstract = "Background: There is an assumption that the mean and biological variation of insulin resistance (IR) is less in polycystic ovary syndrome (PCOS), and intuitively higher in type 2 diabetes (T2DM). To test this hypothesis we compared the mean and biological variation in IR in PCOS to that of T2DM and to age- and weight-matched controls. Methods: Twelve PCOS, 11 matched healthy women; 12 postmenopausal diet-controlled T2DM and 11 matched healthy postmenopausal women were recruited. Blood samples were collected at 4-d intervals on 10 consecutive occasions. The biological variability of IR was derived on duplicate samples. Results: Mean and biological variability of HOMA-IR for PCOS did not differ from T2DM. Both measures were higher than the matched controls. There was no difference in insulin or IR measures between the body mass index matched pre- and postmenopausal women. Percentage b cell function were 208.8{\%}, 62.3{\%}, 106.5{\%} and 111.9{\%}, respectively, in PCOS, postmenopausal women with T2DM, healthy premenopausal and healthy postmenopausal women. Conclusions: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. The clinical trial registration number for this study is ISRCTN65353256.",
author = "Li, {Wei Cho} and V. Jayagopal and Kilpatrick, {E. S.} and Stephen Atkin",
year = "2009",
month = "5",
doi = "10.1258/acb.2008.008146",
language = "English",
volume = "46",
pages = "218--221",
journal = "Annals of Clinical Biochemistry",
issn = "0004-5632",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - The mean and the biological variation of insulin resistance does not differ between polycystic ovary syndrome and type 2 diabetes

AU - Li, Wei Cho

AU - Jayagopal, V.

AU - Kilpatrick, E. S.

AU - Atkin, Stephen

PY - 2009/5

Y1 - 2009/5

N2 - Background: There is an assumption that the mean and biological variation of insulin resistance (IR) is less in polycystic ovary syndrome (PCOS), and intuitively higher in type 2 diabetes (T2DM). To test this hypothesis we compared the mean and biological variation in IR in PCOS to that of T2DM and to age- and weight-matched controls. Methods: Twelve PCOS, 11 matched healthy women; 12 postmenopausal diet-controlled T2DM and 11 matched healthy postmenopausal women were recruited. Blood samples were collected at 4-d intervals on 10 consecutive occasions. The biological variability of IR was derived on duplicate samples. Results: Mean and biological variability of HOMA-IR for PCOS did not differ from T2DM. Both measures were higher than the matched controls. There was no difference in insulin or IR measures between the body mass index matched pre- and postmenopausal women. Percentage b cell function were 208.8%, 62.3%, 106.5% and 111.9%, respectively, in PCOS, postmenopausal women with T2DM, healthy premenopausal and healthy postmenopausal women. Conclusions: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. The clinical trial registration number for this study is ISRCTN65353256.

AB - Background: There is an assumption that the mean and biological variation of insulin resistance (IR) is less in polycystic ovary syndrome (PCOS), and intuitively higher in type 2 diabetes (T2DM). To test this hypothesis we compared the mean and biological variation in IR in PCOS to that of T2DM and to age- and weight-matched controls. Methods: Twelve PCOS, 11 matched healthy women; 12 postmenopausal diet-controlled T2DM and 11 matched healthy postmenopausal women were recruited. Blood samples were collected at 4-d intervals on 10 consecutive occasions. The biological variability of IR was derived on duplicate samples. Results: Mean and biological variability of HOMA-IR for PCOS did not differ from T2DM. Both measures were higher than the matched controls. There was no difference in insulin or IR measures between the body mass index matched pre- and postmenopausal women. Percentage b cell function were 208.8%, 62.3%, 106.5% and 111.9%, respectively, in PCOS, postmenopausal women with T2DM, healthy premenopausal and healthy postmenopausal women. Conclusions: The progression from PCOS to the development of T2DM is unlikely to be due to a further increase in IR (or variability), but rather the progressive failure of pancreatic beta cells with a decrease in insulin production. The clinical trial registration number for this study is ISRCTN65353256.

UR - http://www.scopus.com/inward/record.url?scp=66249148380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249148380&partnerID=8YFLogxK

U2 - 10.1258/acb.2008.008146

DO - 10.1258/acb.2008.008146

M3 - Article

C2 - 19389885

AN - SCOPUS:66249148380

VL - 46

SP - 218

EP - 221

JO - Annals of Clinical Biochemistry

JF - Annals of Clinical Biochemistry

SN - 0004-5632

IS - 3

ER -